Sang Cheul Oh
The University of Texas MD Anderson Cancer Center
ORCID: 0000-0002-0527-6001Also affiliated with University of Oregon, Korea University, Korea University Medical Center, Dong-A University Hospital, Oregon Center For Applied Science (United States), Drug Discovery Laboratory (Norway), Korea University, Universidad del Noreste
Pilot corpus only
This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.
Indexed papers
Why this DataRank?
An author's DataRank is the sum of the DataRanks of all 1 indexed paper attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.
Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.
Read the full methodology →Papers
Driven by 3 papers. Top paper: “Randomized double-blind placebo-controlled phase 2 study of bemarituzumab combined with modified FOLFOX6 (mFOLFOX6) in first-line (1L) treatment of advanced gastric/gastroesophageal junction adenocarcinoma (FIGHT).”.
Peter C. Enzinger, Yoon-Koo Kang, Kensei Yamaguchi, Shukui Qin, Keun-Wook Lee +11 more
Young‐Gyu Eun, Sung Hwan Lee, Sang-Hee Kang, Sun Young Yim, Eui Hyun Kim +13 more
Madeleine R. Ford, Chandler L. Asnes, Sang Cheul Oh, Jonathan Dorogin, Karly M. Fear +7 more